Your Monday morning biotech news roundup

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hey there. Today, we discuss why Sanofi’s stock crashed, what Sarepta’s new Duchenne data will mean for the company and the space, and say goodbye to Bristol Myers Squibb’s chief executive.

The need-to-know this morning
• Novartis said an experimental drug achieved the goals of a Phase 3 study in participants with IgA nephropathy, a type of kidney disease. The Novartis drug, called atrasentan, was the centerpiece of its $3.2 billion acquisition of Chinook Therapeutics earlier this year.
• Day One Pharmaceuticals said the FDA accepted its application for tovorafenib as a treatment for children with low-grade glioma, a type of brain cancer. The drug was granted a priority review with an approval decision expected on April 30, 2024.
United Therapeutics announced a deal to acquire Miromatrix Medical, the maker of an implantable, bioengineered kidney device, for $91 million.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In